What are Empliciti side effects?
In the clinical study that led to the approval of Empliciti (elotuzumab, Bristol-Myers Squibb/AbbVie), the most common side effects seen with Empliciti in combination with Revlimid® (lenalidomide, Celgene) and dexamethasone included:
- Respiratory effects (cough, Infection of the nose and throat [nasopharyngitis], upper respiratory tract infection, or pneumonia)
- Peripheral neuropathy
- Decreased appetite
The most common serious side effects included:
- Low white blood cell counts
- Low platelet counts
- Increased blood sugar
- Low blood calcium
In this study, some patients experienced infusion reactions. The most common symptoms were fever, chills, and high blood pressure.
Some patients developed infections while receiving this drug combination. All patients receiving Empliciti will be monitored for development of infections and treated as necessary.
How are side effects of Empliciti managed?
Patients who experience a moderate or severe infusion reaction will have their Empliciti infusion stopped and their symptoms treated. After symptoms resolve, the infusion may be resumed at a slower rate. Empliciti may be discontinued in patients who experience severe infusion reactions.
Can Empliciti affect laboratory testing?
As Empliciti is an IgG monoclonal antibody, it can be detected on tests used for the clinical monitoring of M protein and may impact the determination of complete response and of disease progression in some patients with IgG myeloma.